Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal
2013 On February 4, 2013
BOULDER, Colo., Jan. 29, 2013
BOULDER, Colo., Jan. 29, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:
ARRY) will report financial results for the second quarter of fiscal 2013 on
Monday, February 4, 2013, and will hold a conference call on Tuesday, February
5, 2013 at 9:00 a.m. eastern time to discuss these results. Ron Squarer,
Chief Executive Officer and Michael Carruthers, Chief Financial Officer will
lead the call.
Conference Call Information
Date: Tuesday, February 5, 2013
Time: 9:00 a.m. eastern time
Toll-Free: (800) 447-0521
Toll: (847) 413-3238
Pass Code: 34113160
Webcast & Conference Call Slides:
A replay of the call will be available as a webcast on www.arraybiopharma.com
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery,
development and commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Array is evolving into a late-stage
development company with significant progress toward generating data to
support our upcoming Phase 3 / pivotal trial decisions. Array-invented MEK162
will be tested in a Phase 3 trial in NRAS melanoma in the next several months
as well as BRAF mutant melanoma later in 2013 (with Novartis). Four other
Array invented drugs are also approaching Phase 3 decisions by the end of
calendar year 2013. These include Array's wholly owned drugs, ARRY-614 and
ARRY-520, and two additional partnered programs, selumetinib (with
AstraZeneca) and danoprevir (with InterMune / Roche). For more information on
Array, please go to www.arraybiopharma.com.
SOURCE Array BioPharma Inc.
Contact: Tricia Haugeto, Array BioPharma Inc., +1-303-386-1193,
Press spacebar to pause and continue. Press esc to stop.